Welcome to visit Acta Anatomica Sinica! Today is
Chinese
Effects of vasoactive intestinal peptide on the activation of glia and the expression of associated inflammatory factors in the substantia nigra of Parkinson’s disease rat models
ZHUANG Wen-xin LIU Zong-yu WANG Xue-jing LI Xiao-jian LIU Jin-cheng FU Wen-yu*
Acta Anatomica Sinica ›› 2016 ›› Issue (2) : 178-184.
Effects of vasoactive intestinal peptide on the activation of glia and the expression of associated inflammatory factors in the substantia nigra of Parkinson’s disease rat models
Objective To investigate the effects of vasoactive intestinal peptide (VIP) on the activation of glia and the expression of associated inflammatory factors in the substantia nigra of the rat model of Parkinson’s disease (PD) induced by 6-hydroxydopamine (6-OHDA). Methods 6-OHDA solution was microinjected into one side of striatum to establish the PD rat model. A total of 32 PD rats were randomly divided into two groups: the VIP group with intraperitoneal injection of the VIP solution 1 ml (20μg/L) and model group with intraperitoneal injection of the normal saline, 16 rats per group. Ten adult normal rats were injected with saline as the control group. The number changes of dopaminergic neurons, microglia that is cluster of diffenentiation 11b (CD11b)-positive cells, astrocytes (GFAP-positive cells) and the expression changes of inflammatory factor (tumor necrosis factor α, cyclooxygenase-2) in substantia nigra of the rats in each group were examined by immunohistochemistry, RT-PCR and Western blotting, respectively. Results Compared to the control group, the numbers of DA neurons, microglia (amoeba-like shaped) and astrocytes in the model group and the VIP group were widely increased (P<0.05), and the expression level of the associated inflammatory factors in the two groups were also increased. In VIP group, the numbers of DA neurons, microglia, astrocytes and the expression level of associated inflammatory factors were decreased compared with the model group (P<0.05). Conclusion VIP has inhibition effects on the activation of microglia and astrocytes, and reduces the expression of related inflammatory factors in the 6-OHDA-induced PD rats. Thus, VIP may protect the DA neurons.
［1］Labandeira-Garcia JL, Rodríguez-Perez AI, Villar-Cheda B, et al. Rho kinase and dopaminergic degeneration a promising therapeutic target for Parkinson’s disease［J］. Neuroscientist, 2015, 21(6): 616-629.
［2］Yan J, Fu Q, Cheng L, et al. Inflammatory response in Parkinson’s disease［J］. Mol Med Rep, 2014, 10(5): 2223-2233.
［3］Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson’s disease［J］. Cell Mol Life Sci, 2013, 70(22): 4259-4273.
［4］Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions［J］. Amino Acids, 2013, 45(1): 25-39.
［5］Waschek JA. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair［J］. Br J Pharmacol, 2013, 169(3): 512-523.
［6］Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates［M］. Sydney:Academic Press, 1985: 87-92.
［7］Wang XX,Fu WY, Zhuang WX, et al. Improvement of rat model of Parkinson’s disease by unilateral striatal two-point and two-spot injection with 6-hydroxydopamine［J］. Chinese Journal of Neuroanatomy, 2015, 31(2): 187-192. (in Chinese)
王晓晓，付文玉，庄文欣，等. 改良纹状体内两点注射6-OHDA法制备大鼠帕金森病模型［J］. 神经解剖学杂志，2015，31(2): 187-192.
［8］Myhre O, Utkilen H, Duale N, et al. Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures［J］. Oxid Med Cell Longev, 2013, 2013: 726954.
［9］Richardson JR, Hossain MM. Microglial ion channels as potential targets for neuroprotection in Parkinson’s disease［J］. Neural Plast, 2013, 2013: 587418.
［10］Streit WJ, Conde JR, Fendfick SE, et al. Role of microglia in the central nervous system’s immune response［J］. Neurol Res, 2005, 27(7): 685-691.
［11］OuchiY, Yagi S, Yokokura M, et al. Neuroinflammation in the living brain of Parkinson’sdisease［J］. Parkinsonism Relat Disord, 2009, 15(Suppl 3): S200-S204.
［12］Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson’s disease［J］. Prog Neurobiol, 2009, 89(3): 277-287.
［13］Zhuang WX, Fu WY, Lü E, et al. Changes of microglia and astrocyte in substantia nigra of 6-OHDA model rats of Parkinson’sdisease［J］. Acta Anatomica Sinica, 2010, 41(3): 344-348.(in Chinese)
庄文欣，付文玉，吕娥，等. 帕金森病大鼠黑质小胶质细胞及星形胶质细胞的变化［J］. 解剖学报，2010, 41(3): 344-348.
［14］Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research［J］. Trends Pharmacol Sci, 2009, 30(4): 174-181.
［15］Saijo K, Crotti A, Glass CK. Regulation of microglia activation and deactivation by nuclear receptors［J］. Glia, 2013, 61(1): 104-111.
［16］Peterson LJ, Flood PM. Oxidative stress and microglial cells in Parkinson’s disease［J］. Mediators Inflamm, 2012, 2012: 401264.
［17］Korkmaz OT, Tuncel N, Tuncel M, et al. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells［J］. J Mol Neurosci, 2010, 41(2): 278-287.
［18］Bensinger SJ, Tontonoz P. A Nurr1 pathway for neuroprotection［J］. Cell, 2009, 137(1): 26-28.
/
| 〈 |
|
〉 |
